Athis Group provides biotech companies with a scientific office and go‑to‑market partner to enter and scale across more than 20 MENA countries. Leveraging AI‑driven compliance and distribution services, they generate country‑specific regulatory paperwork and handle distribution, cutting regulatory approval timelines by up to 50% and streamlining market entry.
Funding
Funding not disclosed
Founders
Product
Problem
Biotech companies face lengthy, complex regulatory approval processes and fragmented distribution networks when entering the diverse markets of the Middle East and North Africa, slowing product launch and limiting revenue growth.
Solution
Athis Group acts as a scientific office and go‑to‑market partner for biotech firms across more than 20 MENA countries. Its AI‑driven compliance engine automatically generates jurisdiction‑specific regulatory documentation, reducing approval timelines by up to 50%. The platform also coordinates local distribution, handling logistics and market entry steps so companies can launch and scale products without building in‑region teams. Expert reviewers verify AI‑generated files to ensure accuracy and compliance. Integrated tools connect with customers’ existing CRMs and marketing platforms, providing a seamless end‑to‑end market entry solution.
Target Audience
Primary customers are biotech startups and established pharmaceutical companies seeking to introduce medical devices or therapeutics into MENA markets, as well as regional distributors requiring regulatory support.
Features
- AI compliance engine that auto‑creates country‑specific regulatory dossiers and filing paperwork
- Expert validation layer that reviews and certifies AI‑generated documents for regulatory accuracy
- Integrated distribution management covering logistics, local partner coordination, and market launch execution across 20+ MENA jurisdictions
- Centralized dashboard that tracks approval status, timelines, and distribution milestones in real time
- Seamless connectivity with CRM, email marketing, and other enterprise tools via standard APIs
- Scalable service model supporting both early‑stage startups and established biotech enterprises expanding their portfolios